Venture Capital | Life Sciences Times

TreeFrog Therapeutics Leases 13,488 Square Feet at Cambridgeport Labs

January 6, 2025

MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio

December 18, 2024

Tasca Therapeutics Launches with $52 Million Series A Financing

December 10, 2024

THIS WEEK'S STORIES

Actineer Appoints Radiopharmaceutical Executive Joseph Oliverio as President and CEO

January 16, 2025

Devonian Appoints Viktoria Krasteva as Chief Financial Officer

January 21, 2025

Wedgewood Appoints Benjamin Daniels as General Counsel and Chief Compliance Officer

January 21, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Tag: Venture Capital

Most Read

Timothy G. Ferris, MD, MPH, Former NHS England and Mass General Executive, Joins Red Cell Partners to Lead Healthcare Practice

Devonian Appoints Viktoria Krasteva as Chief Financial Officer

Wedgewood Appoints Benjamin Daniels as General Counsel and Chief Compliance Officer

Aptyx Amplifies Expertise in Complex Interventional Products With Acquisition of Medical Murray’s North Carolina Facility

EDITOR PICKS

TreeFrog Therapeutics Leases 13,488 Square Feet at Cambridgeport Labs

MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio

Tasca Therapeutics Launches with $52 Million Series A Financing

THIS WEEK'S STORIES

Actineer Appoints Radiopharmaceutical Executive Joseph Oliverio as President and CEO

Devonian Appoints Viktoria Krasteva as Chief Financial Officer

Wedgewood Appoints Benjamin Daniels as General Counsel and Chief Compliance Officer

POPULAR CATEGORY

ABOUT US

FOLLOW US